News
MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus
MinervaXApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the successful completion of a 72 million EUR financing round. The equity financing of 22 million EUR was co-led by new investors Read more…